User login
Achieving the glycemic target—a key goal of diabetes management—remains elusive despite pharmacological and technological advances in insulin delivery and glucose monitoring
FACULTY
Davida F. Kruger, MSN, APN-BC, BC-ADM
Certified Nurse Practitioner
Henry Ford Medical Group
Division of Endocrinology, Diabetes, Bone, and Mineral
Disease
Detroit, Michigan
DISCLOSURES
Davida Kruger discloses that she is on the advisory boards for Abbott; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Novo Nordisk; and sanofi-aventis U.S. LLC; and on the speakers’ bureaus for Animas Corporation, AstraZeneca; Boehringer Ingelheim/Eli Lilly and Company; Dexcom, Inc.; Janssen Pharmaceuticals, Inc.; Novo Nordisk; and Valeritas, Inc. She owns stock in Dexcom, Inc.
Stephen Brunton, MD, discloses that he is on the advisory boards and speakers’ bureaus for AstraZeneca; Boehringer Ingelheim; Becton, Dickinson and Company; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; and Novo Nordisk. He is also on the advisory board for Abbott Diabetes.
Click here to read the supplement.
To receive CME credit, please read the article and on completion, go to www.pcmg-us.org/agpCME to complete the online evaluation and receive your certificate of completion.
Achieving the glycemic target—a key goal of diabetes management—remains elusive despite pharmacological and technological advances in insulin delivery and glucose monitoring
FACULTY
Davida F. Kruger, MSN, APN-BC, BC-ADM
Certified Nurse Practitioner
Henry Ford Medical Group
Division of Endocrinology, Diabetes, Bone, and Mineral
Disease
Detroit, Michigan
DISCLOSURES
Davida Kruger discloses that she is on the advisory boards for Abbott; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Novo Nordisk; and sanofi-aventis U.S. LLC; and on the speakers’ bureaus for Animas Corporation, AstraZeneca; Boehringer Ingelheim/Eli Lilly and Company; Dexcom, Inc.; Janssen Pharmaceuticals, Inc.; Novo Nordisk; and Valeritas, Inc. She owns stock in Dexcom, Inc.
Stephen Brunton, MD, discloses that he is on the advisory boards and speakers’ bureaus for AstraZeneca; Boehringer Ingelheim; Becton, Dickinson and Company; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; and Novo Nordisk. He is also on the advisory board for Abbott Diabetes.
Click here to read the supplement.
To receive CME credit, please read the article and on completion, go to www.pcmg-us.org/agpCME to complete the online evaluation and receive your certificate of completion.
Achieving the glycemic target—a key goal of diabetes management—remains elusive despite pharmacological and technological advances in insulin delivery and glucose monitoring
FACULTY
Davida F. Kruger, MSN, APN-BC, BC-ADM
Certified Nurse Practitioner
Henry Ford Medical Group
Division of Endocrinology, Diabetes, Bone, and Mineral
Disease
Detroit, Michigan
DISCLOSURES
Davida Kruger discloses that she is on the advisory boards for Abbott; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Novo Nordisk; and sanofi-aventis U.S. LLC; and on the speakers’ bureaus for Animas Corporation, AstraZeneca; Boehringer Ingelheim/Eli Lilly and Company; Dexcom, Inc.; Janssen Pharmaceuticals, Inc.; Novo Nordisk; and Valeritas, Inc. She owns stock in Dexcom, Inc.
Stephen Brunton, MD, discloses that he is on the advisory boards and speakers’ bureaus for AstraZeneca; Boehringer Ingelheim; Becton, Dickinson and Company; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; and Novo Nordisk. He is also on the advisory board for Abbott Diabetes.
Click here to read the supplement.
To receive CME credit, please read the article and on completion, go to www.pcmg-us.org/agpCME to complete the online evaluation and receive your certificate of completion.